



Multidisciplinary Association for Psychedelic Studies (MAPS)
1115 Mission Street, Santa Cruz, CA 95060
831-429-6362 | media@maps.org | maps.org

FACT SHEET

MAPS' EFFORTS TO OBTAIN A DEA LICENSE FOR MEDICAL MARIJUANA PRODUCTION FACILITY

MAPS is currently working with Professor Lyle Craker, Ph.D., of the University of Massachusetts-Amherst to **end the NIDA monopoly on marijuana** for research by obtaining a license from the U.S. Drug Enforcement Administration (DEA) for a license to grow marijuana for research. MAPS and Prof. Craker have been working since 1999 to obtain this DEA license.

On August 11, 2016, the DEA announced their intention to grant licenses to additional marijuana growers for research. **Craker reapplied for his license** on February 14, 2017, and received a set of questions from the DEA on March 24. Craker responded to the DEA's questions on April 12, and has not yet received a response.

The main limitation of NIDA marijuana is that it can only be used in academic research, and **could not be sold as a prescription medicine**. Since drugs tested in Phase 3 trials must be the exact same drug that is proposed for marketing after FDA approval, FDA will not accept NIDA marijuana for use in Phase 3 trials, making Phase 3 whole plant marijuana drug development trials impossible.

On July 25, 2018, **eight U.S. Senators sent a letter** to Attorney General Jeff Sessions, setting a deadline of August 10 for DEA to accept or deny for a cause all 26 applications to grow marijuana that DEA has received since August 11, 2016—two years previously—when the DEA under President Obama published a rule in the Federal Register announcing that it would license private producers and end the federal monopoly.

MAPS is preparing a lawsuit against DEA, should the August 10 deadline pass without action

It is now up to Attorney General Jeff Sessions and the Trump administration to end the obstructive NIDA monopoly, encourage independent marijuana research, and take action in granting Craker's license.

More information is available at maps.org/research/mmj/dea-license.

For more information or to schedule an interview, contact Brad Burge, MAPS Director of Strategic Communications, at brad@maps.org or 650-863-6887.